U.S. FDA set to authorize Pfizer, Merck COVID-19 pills this week 
 
 
 
 
 
 

U.S. FDA set to authorize Pfizer, Merck COVID-19 pills this week 

/ 11:12 AM December 21, 2021
Paxlovid, a Pfizer's coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS

Paxlovid, a Pfizer’s coronavirus disease (COVID-19) pill, is seen manufactured in Ascoli, Italy, in this undated handout photo obtained by Reuters on November 16, 2021. Pfizer/Handout via REUTERS

The U.S. Food and Drug Administration is set to authorize COVID-19 treatment pills from both Pfizer Inc and Merck as early as Wednesday, Bloomberg News reported on Tuesday, citing people familiar with the matter.

The two drugs, especially Pfizer’s pill Paxlovid, are seen as promising new oral treatments that can be taken upon onset of symptoms at home to help prevent COVID-19 hospitalizations and deaths.

ADVERTISEMENT

Merck’s drug, molnupiravir, developed with Ridgeback Biotherapeutics, was shown to reduce hospitalizations and deaths by around 30% in a clinical trial of high-risk individuals early in the course of the illness.

Molnupiravir gained a narrow vote in favor of authorization by a panel of advisers to the FDA on Nov. 30.

FEATURED STORIES

Meanwhile, Pfizer’s Paxlovid showed near 90% efficacy in preventing hospitalizations and deaths in high-risk patients.

The FDA did not immediately respond to a request for comment.

Britain in November became the first country in the world to approve Merck’s antiviral drug for use in people with mild to moderate COVID-19 and for those who have at least one risk factor for developing severe illness.

The United States has a contract to buy as many as 5 million courses of Merck’s drug, and 10 million courses of Pfizer’s treatment.

Subscribe to our newsletters! Get updates right into your inbox

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.
Don't miss out on the latest news and information.
TAGS:
For feedback, complaints, or inquiries, contact us.

Subscribe to our newsletters!
Get Updates right into your inbox

By providing an email address. I agree to the Terms of Use and
acknowledge that I have read the Privacy Policy.




We use cookies to ensure you get the best experience on our website. By continuing, you are agreeing to our use of cookies. To find out more, please click this link.